e-learning
resources
ERJ
2013
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country
Jenkins Helen E., Plesca Valeriu, Ciobanu Anisoara, Crudu Valeriu, Galusca Irina, Soltan Viorel, Serbulenco Aliona, Zignol Matteo, Dadu Andrei, Dara Masoud, Cohen Ted
Source:
Eur Respir J 2013; 42: 1291-1301
Journal Issue:
November
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jenkins Helen E., Plesca Valeriu, Ciobanu Anisoara, Crudu Valeriu, Galusca Irina, Soltan Viorel, Serbulenco Aliona, Zignol Matteo, Dadu Andrei, Dara Masoud, Cohen Ted. Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J 2013; 42: 1291-1301
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country
Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020
Year: 2021
Trends of multidrug-resistant tuberculosis clustering in Portugal
Source: ERJ Open Res, 5 (1) 00151-2018; 10.1183/23120541.00151-2018
Year: 2019
Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration
Source: Eur Respir J 2016; 47: 686-688
Year: 2016
HIV and multidrug-resistant tuberculosis: overlapping epidemics
Source: Eur Respir J 2014; 44: 251-254
Year: 2014
Determinants of multidrug-resistant tuberculosis (MDR-TB) in Belarus
Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview
Year: 2012
TB drug resistance in high-incidence countries
Source: Eur Respir Mon 2012; 58: 95-110
Year: 2012
Detection of latent tuberculosis in a low-prevalence country
Source: Annual Congress 2007 - Gamma-interferon-based tests to diagnose tuberculosis infection and disease
Year: 2007
Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in a metropolitan city
Source: Eur Respir J 2013; 41: 901-908
Year: 2013
Estimating the prevalence of latent tuberculosis in a low-incidence setting: Australia
Source: Eur Respir J, 52 (6) 1801218; 10.1183/13993003.01218-2018
Year: 2018
Primary drug resistance against mycobacterium tuberculosis in a high burden country
Source: Eur Respir J 2006; 28: Suppl. 50, 587s
Year: 2006
Analysis of multidrug-resistant tuberculosis
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1
Year: 2014
Multidrug-resistant tuberculosis in children: evidence from global surveillance
Source: Eur Respir J 2013; 42: 701-707
Year: 2013
Changes in treatment for multidrug-resistant tuberculosis according to national income
Source: Eur Respir J, 56 (5) 2001394; 10.1183/13993003.01394-2020
Year: 2020
Treatment outcome of MDR pulmonary tuberculosis from a high burden developing country
Source: Annual Congress 2008 - Outcomes of tuberculosis treatment
Year: 2008
Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013
Is prevalence of MDR TB and XDR TB decreasing in a tertiary care hospital in India?
Source: International Congress 2017 – MDRTB: detection and management
Year: 2017
Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk
Source: Eur Respir J 2012; 39: 1425-1431
Year: 2012
The global risk of dying from multidrug-resistant tuberculosis (MDR-TB)
Source: International Congress 2014 – Tuberculosis epidemiology: novel features
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept